Market closed
Cue Biopharma/$CUE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cue Biopharma
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Ticker
$CUE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
53
Website
Cue Biopharma Metrics
BasicAdvanced
$80M
-
-$0.90
1.63
-
Price and volume
Market cap
$80M
Beta
1.63
52-week high
$2.37
52-week low
$0.45
Average daily volume
233K
Financial strength
Current ratio
2.219
Quick ratio
2.119
Long term debt to equity
10.463
Total debt to equity
37.499
Interest coverage (TTM)
-39.69%
Management effectiveness
Return on assets (TTM)
-50.18%
Return on equity (TTM)
-131.15%
Valuation
Price to revenue (TTM)
6.598
Price to book
3.01
Price to tangible book (TTM)
3.01
Price to free cash flow (TTM)
-1.641
Growth
Revenue change (TTM)
149.53%
Earnings per share change (TTM)
-24.04%
3-year revenue growth (CAGR)
10.00%
3-year earnings per share growth (CAGR)
-15.97%
What the Analysts think about Cue Biopharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cue Biopharma stock.
Cue Biopharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cue Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cue Biopharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cue Biopharma stock?
Cue Biopharma (CUE) has a market cap of $80M as of February 26, 2025.
What is the P/E ratio for Cue Biopharma stock?
The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of February 26, 2025.
Does Cue Biopharma stock pay dividends?
No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Cue Biopharma dividend payment date?
Cue Biopharma (CUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Cue Biopharma?
Cue Biopharma (CUE) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.